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Abstract
It is not known whether computerized cognitive assessments, like the CogState battery, are 
sensitive to preclinical cognitive changes or pathology in people at risk for Alzheimer’s disease 
(AD). In 469 late middle-aged participants from the Wisconsin Registry for Alzheimer’s 
Prevention (mean age 63.8±7 years at testing; 67% female; 39% APOE4+), we examined 
relationships between a CogState abbreviated battery (CAB) of seven tests and demographic 
characteristics, traditional paper-based neuropsychological tests as well as a composite cognitive 
impairment index, cognitive impairment status (determined by consensus review); and biomarkers 
for amyloid and tau (CSF phosphorylated-tau/Aβ42 and global PET-PiB burden) and neural injury 
(CSF neurofilament light protein). CSF and PET-PiB were collected in n=71 and n=91 
participants, respectively, approximately four years prior to CAB testing. For comparison, we 
examined three traditional tests of delayed memory in parallel. Similar to studies in older samples, 
the CAB was less influenced by demographic factors than traditional tests. CAB tests were 
generally correlated with most paper-based cognitive tests examined and mapped onto the same 
cognitive domains. Greater composite cognitive impairment index was associated with worse 
performance on all CAB tests. Cognitively impaired participants performed significantly worse 
compared to normal controls on all but one CAB test. Poorer One Card Learning test performance 
was associated with higher levels of CSF phosphorylated-tau/Aβ42. These results support the use 
of the CogState battery as measures of early cognitive impairment in studies of people at risk for 
AD.
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1 INTRODUCTION
CogState is a computerized cognitive battery spanning domains of memory, executive 
function, and speed of processing. It has been shown to have acceptable stability and test-
retest reliability with minimal practice effects at short test-retest intervals in groups of 
healthy controls and patients at various stages of cognitive impairment and dementia [1, 2]. 
Computerized testing, such as the CogState battery, may hold potential for detecting early 
cognitive dysfunction associated with preclinical Alzheimer’s disease (AD)[3].
Previous studies have demonstrated differences between healthy controls, Mild Cognitive 
Impairment (MCI), and AD, with the most pronounced impairments in the latter two groups 
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on CogState tests of learning and memory [4, 5]. The vast majority of studies investigating 
biomarker correlates of the CogState have focused on neuroimaging biomarkers, with a 
particular focus on PET amyloid imaging. The majority [3, 6–11] but not all [12] have found 
an association with amyloid. One study also found an association with hippocampal volume 
and glucose metabolism [12]. Of note, the majority of published studies that have examined 
biomarkers and the CogState battery have been performed on two cohorts, the Australian 
Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) and the Mayo Clinic 
Study on Aging. The present study adds the largest long-term study of healthy relatives of 
persons with Alzheimer’s disease, the Wisconsin Registry for Alzheimer’s Prevention 
(WRAP), to the cohorts simultaneously investigating biomarkers and the CogState battery. 
Additionally, there is a dearth of information in the current scientific literature on the 
association between the CogState battery and potentially informative cerebrospinal fluid 
(CSF) biomarkers for Alzheimer’s pathology and neural injury. This is an important gap to 
fill as recent work suggests that CSF biomarkers become abnormal in the earliest stages of 
AD, before changes in amyloid positron emission tomography are apparent [13, 14].
The present study investigated whether CogState is sensitive to pre-dementia cognitive 
dysfunction and early accumulation of AD pathology during late-midlife. First we explored 
relationships between CogState tests and demographic characteristics. Next, we examined 
relationships between CogState tests and three measures of cognitive function: individual 
scores on traditional paper-based neuropsychological tests, a composite cognitive 
impairment index, and cognitive status (cognitively impaired vs. cognitively normal). 
Finally, we investigated sensitivity to underlying AD pathology by examining whether 
biomarkers for amyloid and tau (CSF phosphorylated-tau/Aβ42 and global PET-PiB burden) 
and neural injury (CSF neurofilament light protein) predicted CogState performance 
approximately four years later. We hypothesized that performance on the CogState battery 
would be relatively robust to demographic variability but would be associated with cognitive 
functioning as well as biomarkers for AD pathology. Additionally, to evaluate whether the 
CogState battery may be more robust to demographics and more associated with disease 
outcomes compared to traditional neuropsychological tests, we also examined relationships 
of three traditional tests of delayed memory with demographics, cognitive function, and 
biomarkers and provide effects sizes for comparison between the cognitive measures. By 
examining relationships between the CogState battery and multiple measures of early 
cognitive dysfunction as well as biomarkers for amyloid and neural injury in an at-risk 
cohort, this study investigated whether the CogState battery is sensitive to early cognitive 
and pathological changes suggestive of incipient AD.
2 MATERIALS AND METHODS
2.1 Participants
WRAP is a longitudinally followed cohort designed to identify biological and lifestyle risk 
factors associated with development of dementia due to Alzheimer’s disease [15–17]. The 
WRAP study consists of 1,545 participants (mean age=53.6±6.6 years at first cognitive 
assessment), of which 72.4% have a parental family history of dementia due to Alzheimer’s 
disease. In 2014, the CogState was added to the assessment protocol for each visit; data used 
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in this paper represents first CogState for each person, although the overall WRAP visit 
number varies from 2 to 5 (3.2% of participants were administered the CogState at visit 2, 
19.8% at visit 3, 24.5% at visit 4, and 52.5% at visit 5). Participants were selected for the 
current analyses if they had completed at least one of the seven CogState tests that have been 
added to the WRAP battery. The University of Wisconsin Institutional Review Board 
approved all study procedures, informed consent was obtained for all participants, and the 
work described has been carried out in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki).
Cognitive status was determined via consensus review conference by a panel of experts in 
cognitive aging and dementia, including clinical neuropsychologists, physicians, and nurse 
practitioners for the same WRAP visit that CogState was administered. The consensus panel 
reviews cognitive performance as well as additional information in the participant’s chart 
(e.g., medical history, social history, informant reports) to determine final cognitive status. A 
cut-off of 1.5 standard deviations below a robust normative sample (e.g., low-risk WRAP 
participants who remained normal throughout the study;[17, 18]) was used to define 
impairment on cognitive measures. A diagnosis of clinical MCI was based on the NIA-AA 
criteria [19, 20] including subjective cognitive decline, objective impairment in one or more 
cognitive domains, and preservation of functional abilities. The construct of early MCI was 
developed to identify cognitive decline expected to precede a clinical MCI diagnosis, and 
identifies individuals who exhibit lower than expected performance on neuropsychological 
measures (e.g., ≤1.5 SD below demographically-corrected robust norms), but do not 
necessarily report subjective cognitive decline. Of the 469 participants who were 
administered the abbreviated CogState battery, 10 met criteria for clinical MCI, another 60 
exhibited subtle deficits indicative of early MCI, and 6 were classified as having a cognitive 
impairment primarily due to depression rather than MCI. The clinical MCI and early MCI 
participants were grouped together into a cognitively impaired group and the remaining 393 
unimpaired participants were considered cognitively normal (Table 1). The 6 individuals 
with potential non-MCI cognitive impairment were included in the total sample but in 
neither the cognitively impaired nor normal groups. None of the cognitively impaired 
participants had dementia.
2.2 Measures of cognition
2.2.1 CogState—Select tests from the CogState battery were administered on a laptop to 
participants after completing the non-computerized assessments. This CogState abbreviated 
battery (CAB) included a test of delayed visual memory through paired associate learning 
(Continuous Paired Associate Learning, CPAL), speed of visual processing (Groton Maze 
timed chase test, GMCT), executive function (Groton Maze learning test, GML), delayed 
recall (Groton Maze learning test delayed recall, GMR), and working memory (One-card 
learning, OCL; One-back memory, ONB; and Two-back memory, TWOB). For CPAL, 
GML, and GMR, total number of errors was assessed; for GMCT moves per second was 
assessed; and for the three card tasks (OCL, ONB, and TWOB) accuracy was assessed using 
the arcsine proportion to correct for normality. Data were only included that passed criteria 
for completion and integrity. To be considered “complete,” at least 75% of all responses 
needed to be observed for the card tasks (OCL, ONB, TWOB), all 28 steps of the maze path 
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needed to be completed for the Groton Maze tasks (GML, GMR), and all rounds needed to 
be completed for CPAL; there is no completion check for GMCT. Integrity checks were 
completed for the three card tasks only and were satisfied if the proportion correct was 
above chance (at least 50% correct). 99.4–100% of participants passed completion checks 
for each of the seven tests and 97.5–99.6% passed the integrity checks for each of the three 
card tasks. Selection of test outcomes, transformations to correct for normality, and tests of 
completion and integrity were performed per the recommendations from the CogState 
manual [21]. Additionally, not all participants finished the full CAB, with more missing data 
for tests administered at the end of the battery. All participants finished at least one test and 
98.7% finished all seven tests. Non-completion of the CAB was due to fatigue, frustration, 
or technical difficulties. Missing data and checks for completion and integrity are 
summarized in Supplementary Table 1.
2.2.2 Traditional neuropsychological battery—A comprehensive neuropsychological 
battery was performed at each WRAP visit. For this analysis, non-computer tests were 
selected that measure memory, language, executive function, or global cognitive function. 
These included Rey Auditory Verbal Learning Test (RAVLT [22]) total trials 1–5 and 
delayed recall; Wechsler Memory Scale-Revised (WMS-R [23]) Logical Memory I and II 
(immediate and delayed recall, respectively); Brief Visuospatial Memory Test-Revised 
(BVMT-R [24]) immediate and delayed recall; Boston Naming Test–2nd Edition (BNT 
[25]); Animal Naming [26]; Controlled Oral Word Association Test phonemic fluency (CFL 
[27]); Stroop Neuropsychological Screening Test color-word interference trial (Stroop [28]); 
Trail Making Test (TMT [29]) Parts A and B; Wechsler Adult Intelligence Scale-Revised 
(WAIS-R [30]) Digit Symbol; Wechsler Adult Intelligence Scale-Third Edition (WAIS-III 
[31]) Letter Number Sequencing and Digit Span subtests; and Mini Mental State 
Examination (MMSE [32]).
2.2.3 Composite cognitive impairment index—A composite cognitive impairment 
index (CCII) was calculated using a set of eight cognitive measures: TMT A and B, WAIS-
III Digit Span forward and backward, RAVLT total trials 1–5 and delayed recall trial, BNT, 
and MMSE. Visits were excluded when fewer than four of these measurements were 
available. We applied the progression score model [33–35] to align individuals along a linear 
cognitive trajectory based on their longitudinal cognitive measure profiles, adjusting for 
inter-individual differences in rates of change. The composite cognitive impairment index 
computed using this method is an individualized summary of the eight cognitive measures, 
with higher values indicating lower cognitive performance in all measures. Different from 
previous approaches, we accounted for correlations among cognitive measures. To remove 
confounding effects of age at entry into WRAP, a composite was estimated at age 65 based 
on an approximate expression for the time derivative of the CCII.
2.3 Biomarker collection
Some WRAP participants were recruited for biomarker substudies which do not necessarily 
correspond to a specific WRAP visit. We examined PET and CSF biomarker data, which 
were collected independently and up to several years prior to the CogState.
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2.3.1 PET-PiB—Detailed methods for [C-11] PiB radiochemical synthesis, PiB-PET 
scanning with a 70 minute dynamic acquisition, and distribution volume ratio map 
generation using the Logan method and the cerebellum as a reference region have been 
described previously [36]. PiB-PET images were registered to a T1-weighted anatomical 
scan collected on a GE 3.0 Tesla MR750 (Waukesha, WI) using an 8 channel head coil [36, 
37]. A composite measurement of global amyloid derived from eight bilateral ROIs (angular 
gyrus, anterior cingulate gyrus, posterior cingulate gyrus, frontal medial orbital gyrus, 
precuneus, supramarginal gyrus, middle temporal gyrus, and superior temporal gyrus) was 
calculated as described previously [38, 39]. N=91 participants underwent PiB-PET imaging 
approximately 4.1 years (SD 0.66, range 2.0–5.3) prior to CAB testing.
2.3.2 Cerebrospinal fluid—CSF was collected as described previously [40, 41]. CSF 
Aβ42 and phosphorylated-tau (p-tau) were quantified with sandwich ELISAs (INNOTEST 
β-amyloid1–42 and Phospho-Tau[181P], respectively; Fujirebio Europe, Ghent, Belgium). 
CSF p-tau/Aβ42 was calculated by dividing CSF p-tau by CSF Aβ42. CSF neurofilament 
light protein (NFL) was measured with a sandwich ELISA method as described by the 
manufacturer (NF-light ELISA kit, UmanDiagnostics AB, Umeå, Sweden). N=70 
participants underwent baseline lumbar puncture approximately 3.7 years (SD 1.11, range 
1.17–5.33) prior to CAB testing.
CSF assays were performed in two batches. We corrected for batch differences using simple 
linear regression (SLR) on a subset of CSF samples (n=96 from the entire CSF database, not 
just from individuals who had also undergone CogState testing) that were assayed in both 
batches. SLR was also used to test whether batch corrections were necessary using null 
hypothesis tests of a slope of 1 and an intercept of 0. If there was insufficient evidence to 
suggest that any of these hypotheses should be rejected, raw values from both batches were 
used; otherwise, predictions were made with SLR on CSF values from batch 2 as if they had 
been tested in batch 1. All analyses for CSF batch corrections were performed using R 
version 3.2.3 using the base “lm” function.
2.4 Statistical analyses
Significance was inferred at a Bonferroni-corrected p-value for seven CogState tests (p<.
05/7=.007) unless otherwise stated.
2.4.1 Correlations between CAB, demographics, and traditional 
neuropsychological tests—For dichotomous characteristics (sex, parental family 
history of AD, and APOE4 carriage), t-tests were performed on the seven CogState 
variables. For continuous variables (total years of education; literacy as measured by 
baseline Wide Range Achievement Test reading raw score; age at testing; depression as 
measured by the Center for Epidemiologic Studies Depression Scale; and traditional paper-
based neuropsychological tests) and ordinal variables (e.g., computer familiarity as 
measured on a Cognitive Activities questionnaire), we performed Spearman rank-order 
correlations. Cohen’s d were calculated for t-tests and effect sizes of .2, .5., and .8 are 
interpreted as small, medium, and large, respectively. Correlation coefficients of .1, .3., and .
5 are interpreted as small, medium, and large effect sizes, respectively [42].
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To determine whether CAB is more robust to education and other demographic 
characteristics compared to traditional paper-based tests, we also examined correlations 
between demographics and select traditional neuropsychological tests. Numerous studies 
have identified delayed episodic memory as one of the earliest cognitive domains to become 
impaired in AD [43–45], likely during the preclinical timeframe; therefore, to reduce the 
number of multiple comparisons, we selected three tests of delayed memory from our 
neuropsychological battery: RAVLT delayed recall, Logical Memory delayed recall, and 
BVMT-R delayed recall. For the analyses described here and as follows, these three delayed 
recall tests served to provide context for interpreting the CAB findings compared to more 
traditional neuropsychological testing formats.
2.4.2 ANCOVA comparing cognitive groups on CAB performance—Scores on the 
CAB of cognitively impaired participants were compared to cognitively normal controls by 
ANCOVA controlling for age, literacy, sex, APOE4 positivity, family history of AD, and 
computer familiarity. Effect sizes by partial eta squared are reported. Small, medium, and 
large effect sizes for eta squared are .01, .06, and .14, respectively [46]. We did not compare 
cognitive groups on the select traditional neuropsychological tests identified in section 2.4.1 
because these tests were evaluated during diagnostic consensus conference.
2.4.3 Associations between the individual cognitive tests and composite 
cognitive impairment index—In addition to examining individual neuropsychological 
tests, we investigated whether CCII, which takes advantage of longitudinally measured 
cognition up to (and including) the visit at which the CAB was administered, is associated 
with performance on the CAB. We ran regression analysis for each of the seven CogState 
tests, with the CAB test as the dependent variable and CCII as the independent variable of 
interest, controlling for age at CAB testing, literacy, sex, APOE4, family history of AD, and 
computer familiarity. Variance inflation factors (VIF) and tolerance were assessed and 
deemed normal if tolerance was greater than .1 and VIF was less than 10. Cohen’s f2 for 
hierarchical regression, R2, and R2-change (the change in R2 after adding CCII to the model) 
are reported. Cohen’s f2 of 0.02, 0.15, and 0.35 are considered small, medium, and large, 
respectively [46]. For comparison, parallel models were run for the three traditional delayed 
recall tests except RAVLT delayed which was used to calculate CCII.
2.4.4 Cognition and biomarker associations
2.4.4.1. Biomarker normalization and dichotomization: Although PiB burden was 
skewed to the right, traditional transformations were ineffective at improving normality. 
Instead, we chose to examine PiB burden untransformed (with and without an outlier) as a 
continuous variable and as a dichotomous variable (i.e., PiB positive vs. PiB negative) with 
the goal of capturing the hypothesized underlying binomial distribution [47]. A cut-off value 
for PiB positivity was determined using receiver operating characteristic (ROC) analysis in 
pROC R Statistical Package [48] bootstrapping 2000 times with replacement and 
stratification of sample. We used expert visual ratings of PiB positive or negative that have 
been described previously as the diagnostic groups [36, 37]. Supplementary Figure 1 depicts 
the ROC plot with an area under the curve of .974. A threshold was determined using 
Youden’s Index which identifies the PiB burden value that maximizes both sensitivity and 
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specificity [49]. A threshold of 1.19 was identified which corresponded to sensitivity of .938 
and specificity of .917.
2.4.4.2. Cognition and biomarkers associations: We performed Spearman correlations 
between CAB variables and three biomarkers of interest: CSF p-tau/Aβ42, CSF NFL, and 
global PiB burden (with and without an outlier). T-tests were performed to compare 
CogState performance between PiB+ and PiB− groups. Furthermore, we investigated 
promising correlations (significant or trending) through multiple regressions with CAB 
scores as the dependent variable and biomarker as the independent variable of interest. In 
addition to the covariates used in the CCII regression models, we additionally controlled for 
the interval from biomarker collection to CAB testing (CSF to CAB 44.3±13.5 months; 
PET-PiB to CAB 49.6±7.9 months) because the biomarker assessments were conducted at 
various time points prior to administration of the CAB. Comparable models with ANCOVA 
were performed for PiB positivity. VIF and tolerance were again inspected. Because we 
expected smaller effect sizes, we optimized statistical power by not adjusting for multiple 
comparisons in these cognition/biomarker analyses (i.e., p<.05 was considered significant). 
For comparison, we also analyzed the relationships between the three traditional 
neuropsychological tests (see 2.4.1) and biomarkers.
3 RESULTS
Participant characteristics are summarized in Table 1.
3.1 Correlations between the CAB, demographics, and traditional neuropsychological 
tests
None of the seven CAB scores or traditional delayed memory scores differed significantly 
by APOE4 status or family history. Females performed better on CPAL (fewer errors; p<.
001, Cohen’s d= 0.39) and on GMCT (more moves per second; p=.004, Cohen’s d=−0.27), 
similar to traditional verbal memory tests [RAVLT delayed (p<.001, Cohen’s d=−0.81) and 
Logical Memory delayed (p=.005, Cohen’s d=−0.26)]. Spearman rank-order correlation 
coefficients are reported in Table 2 for age, education, literacy, depression, and computer 
familiarity. Effect sizes for all associations with demographic and CAB variables were small 
except between age and GMCT and age and TWOB, which were both moderate. A large 
effect size was observed for sex on RAVLT delayed and a moderate effect size was observed 
for literacy on Logical Memory delayed. All other effect sizes were small.
The majority of neuropsychological test scores and CAB scores were significantly 
correlated. A correlation matrix is provided as Table 3 with moderate correlations in bold. 
Within CogState correlations are reported in Supplementary Table 2.
3.2 CAB performance by cognitive status
After controlling for risk factors and demographics, CAB performance differed between 
individuals who were cognitively impaired and cognitively normal controls for all CAB tests 
(p<.007, Table 4, Figure 1) except ONB. All effect sizes were small except GMR, which was 
moderate. There were several other significant (p<.05) predictors in the CogState models. 
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Age and literacy were significant predictors of CogState performance in every model except 
ONB. Sex was a significant predictor for CPAL, GML, and GMR. APOE4 was a significant 
predictor of CPAL and GML. Computer familiarity was significantly associated with GMCT 
and family history was significantly associated with OCL.
3.3 Associations between individual cognitive tests and composite cognitive impairment 
index
VIF and tolerance were in the normal range for all models. CCII significantly predicted 
performance on all CAB tests (p<.007, Table 5, Figure 2). Age at CAB testing (CPAL, 
GMCT, GML, OCL, TWOB) and sex (GML, GMR, TWOB) were common additional 
predictors of CAB performance (p<.05). Computer familiarity also significantly predicted 
GMCT only (p<.05). Logical memory delayed and BVMT-R delayed also significantly 
predicted CCII (p<.007, Table 5). Effect sizes were moderate for CPAL, GMR, Logical 
Memory delayed, and BVMT-R delayed; all others were small.
3.4 Associations between cognition and biomarkers
Based on null hypothesis testing, p-tau/Aβ42 but not NFL required batch correction. Overall, 
biomarkers were not strongly associated with the CAB or delayed recall scores in the subset 
with CSF (n=70) or PiB (n=91), with significant and trending associations only present for 
the CSF biomarkers. Spearman correlations are reported in Table 6. When significant or 
trending correlations were investigated further in regression and ANCOVA models, only 
CSF p-tau/Aβ42 (Figure 3) was a significant predictor of OCL performance (β=−1.13, t=
−3.09, f2=.162, R2=.203, R2-change=.129, p=.003).
4 DISCUSSION
Computer-based psychological batteries offer several advantages over traditional 
psychological (often paper-and-pencil-based) tests including reduced testing time and 
administrative training, standardization of test administration, accurate measures of response 
latencies, and reduced risk of human error [50, 51]. Consequently, there has been a shift in 
interest to computer-administrated psychological batteries. The CogState battery is one such 
computerized battery that has been shown to have good accuracy, efficiency, and stability for 
repeated assessment, as well as demonstrated sensitivity to cognitive impairment and 
cognitive change [52, 53]. Here we evaluated performance on an abbreviated CogState 
battery at a single time point in relation to demographics characteristics, traditional 
neuropsychological tests, cognitive status, a composite cognitive score, and biomarkers in a 
late-middle-aged sample from the WRAP cohort. We also sought to provide a context for 
assessing the sensitivity of the select CogState tests by examining traditional gold-standard 
tests of delayed memory in parallel. Our findings that select CogState tests were associated 
with several measures of early cognitive impairment and a CSF biomarker for AD pathology 
support the use of the CogState battery as a neuropsychological testing tool during the 
preclinical timeframe.
Our results are consistent with previous studies of CogState showing generally weak 
relationships with demographic variables and weak to moderate associations with traditional 
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neuropsychological tests [5, 11, 54]. Associations with demographic characteristics were 
generally small, with the most consistent relationships observed with age and sex. GMCT 
was most affected by demographic characteristics like computer familiarity, education, and 
literacy. Traditional delayed memory tests were more strongly and consistently associated 
with demographic characteristics (e.g., all three tests were significantly correlated with age, 
education, and literacy) than CogState measures, supporting the theory that the CogState 
battery is more robust to education level compared to traditional paper-based 
neuropsychological tests.
The majority of the CAB and traditional tests were significantly correlated, and moderate 
correlation coefficients were generally observed between tests of comparable cognitive 
domains. CPAL was moderately correlated with almost all traditional tests of memory 
examined. The Groton Maze tests combine skills of executive function, learning, and 
memory and correspondingly were moderately correlated with traditional 
neuropsychological tests of memory (RAVLT, BVMT) and executive function (Stroop, TMT, 
WAIS-R Digit Symbol), as well as Animal Naming. Interestingly, GMCT, which is generally 
considered a task to introduce subjects to the Groton Maze learning and delayed recall tasks, 
had the most frequent associations with other neuropsychological tests of the three maze 
paradigms; GML and GMR were both only moderately correlated with BVMT-R immediate 
and delayed recall. Of the card tests, OCL, a visual memory test, was moderately correlated 
with RAVLT delayed recall and TMT Part B; and TWOB, a test of working memory, was 
moderately correlated with three executive functioning tasks: Stroop, TMT Parts A and B, 
and WAIS-R Digit Symbol. Moderate correlations between CogState and traditional 
neuropsychological tests, therefore, were generally consistent with the domains they are 
expected to probe.
Curiously, although ONB is included in CogState’s recommended Alzheimer’s Battery [4], 
it was the most weakly correlated with any traditional neuropsychological tests, often not 
reaching even liberal thresholds for statistical significance (i.e., p<.05). Performance on 
ONB was also the only CAB test that did not differ between cognitively normal and 
cognitively impaired groups. Given the relative health and younger age of our sample, we 
suspect this test was too easy for our participants and resulted in a marked ceiling effect. 
Indeed, participants only made on average two errors on ONB with one-fourth of the sample 
making zero errors and 93% of participants making five or fewer errors. This contrasts with 
the other two card tasks: an average of five errors were made on TWOB with only 7% 
making zero errors, and an average of 26 errors were made on OCL and no participants 
made fewer than 10 errors. Others have found differences between diagnostic groups on 
ONB test using reaction time instead of accuracy, which could be less prone to ceiling 
effects and may be more applicable in cohorts without clinical dementia [11]. Its major 
function in the battery we selected was to serve as a warm up test for the more difficult 
TWOB task. Our results suggest that ONB accuracy is less useful in late middle-age.
One of the earliest studies of the CogState battery showed that 15 patients with MCI 
declined within a one-year period on a CogState memory task (Continuous Learning Test) 
compared to age, education, IQ, and gender matched controls; while decline was not 
detectable using routine memory tests in either group [55]. While we were not able to 
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address decline in CogState performance across groups with only one time point of CAB 
administration, we did incorporate the extensive longitudinal data that has been collected in 
WRAP using traditional neuropsychological tests to create a composite of cognitive 
impairment. Unlike simple z-score composites, the CCII adjusts for inter-individual 
differences in rates of change, removes confounding effects of age at study entry, and 
accounts for correlations among cognitive measures. This type of cognitive impairment 
index could be a useful tool against which to measure novel tests of cognitive/clinical status 
and progression, like the CogState battery. Both the CAB and traditional delayed memory 
tests were associated with CCII. Effect sizes were moderate for CPAL, GMR, Logical 
Memory delayed, and BVMT-R delayed with the largest effect size observed for CPAL. 
Since GMR, CPAL, Logical Memory delayed recall, and BVMT-R delayed recall all 
measure delayed memory, it would seem that this cognitive domain is either driving the 
CCII calculation or that delayed recall tests—either computerized or not—are the most 
sensitive to early cognitive decline, as measured by this unique composite cognitive 
impairment index.
With the exception of ONB, cognitively impaired individuals performed significantly worse 
on the CAB tests compared to cognitively normal controls. The difference was generally 
small, with the most marked difference observed for GMR, a tests of delayed memory, 
suggesting that GMR is most sensitive to early cognitive dysfunction among the CAB 
variables.
After correcting for covariates, only CSF p-tau/Aβ42 was associated with worse performance 
on OCL test, which uses a pattern separation paradigm to measure visual memory. Most 
previous studies that have found an association between biomarkers and CogState tests have 
evaluated intra-individual cognitive decline based on longitudinally acquired CogState 
testing rather than a single time point [3, 6–8, 56]. In contrast, a study with a single CogState 
battery evaluation did not find an association between CogState test performance and 
amyloid PET [12]. The latter study did, however, find relatively weak associations between 
CogState test performance and FDG-PET hypometabolism and smaller hippocampal 
volumes, suggesting that a single time point could still be informative of underlying 
pathology. While we were able to detect a relationship between a CSF measure of co-
occurring amyloid and tau pathology and one CogState test but none of the three traditional 
delayed memory tests, it remains unclear whether CogState tests at one time point would 
substantially improve inference about underling pathology beyond what is possible with 
traditional paper-based neuropsychological tests.
4.1 Limitations
The primary limitations of this study are that biomarkers were collected several years before 
CAB administration and that we do not yet have serial CAB testing, both of which constrain 
our ability to make stronger inferences about the CogState battery and underlying pathology. 
The correlational analyses between the CAB and traditional tests may have also been 
affected by the number of times of previous administration on the pencil-and-paper tests 
which are known to have practice effects [57, 58]. Due to testing duration considerations, we 
only selected two of the four CogState card tasks; while the selected tasks utilize the 
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cognitive domains of primary interest to this study (learning and memory), this may limit the 
comparability to other studies which used all four card tasks. It is also worth noting again 
the smaller samples sizes in the biomarkers analyses; it is possible that we lacked sufficient 
power to detect important associations between these cognitive tests and underlying 
pathology; indeed, although most correlations between p-tau/Aβ42 and the CAB tests were 
considered not significant, all were in the expected direction. Additionally, our study cohort 
was largely Caucasian and well educated, and so generalizability is restricted. This 
homogeneity may have also reduced our ability to detect demographic correlates of the 
CAB. It will be important to perform similar studies with CogState in more diverse 
populations. Longitudinal clinical outcomes will be important for evaluating prognostic 
utility of the CAB.
4.2 Conclusions
Overall this study provided support for the use of the CAB in evaluating cognitive function 
during late-middle-age. The present study is unique in that the WRAP participants are 
younger and cognitively healthier than the typical clinical MCI groups that have been 
investigated in prior studies; the population is also enriched for higher risk of developing 
MCI and dementia due to parental history of AD. Although prior studies provide evidence 
that the CogState battery can differentiate between healthy controls and clinical MCI in 
older age, this study suggests that it is also sensitive to decline in early MCI, before clinical 
symptoms and multiple objective cognitive impairments are apparent. It further provides 
evidence for an association between one CogState test in particular (OCL) and an important 
pathological marker for preclinical AD, CSF p-tau/Aβ42. However, it also suggests that 
CogState at a single time point may not substantially improve preclinical AD detection over 
traditional neuropsychological tests. Still, its administration offers several advantages over 
paper-based tests, which make it desirable for large, longitudinal studies with demographic 
variability. Future directions will focus on longitudinally collected CogState data in the 
WRAP cohort and examination of a greater array of biomarkers.
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Figure 1. 
Boxplots depicting comparison of Cognitively Normal and Cognitively Impaired groups on 
mean performance on CogState tests. Accuracy was transformed using the arcsine 
proportion to correct for normality.
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Figure 2. 
Relationships between CogState tests and a composite cognitive impairment index estimated 
at age 65. 95% confidence intervals for the regression line are displayed. Accuracy was 
transformed using the arcsine proportion to correct for normality.
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Figure 3. 
Partial regression plot of CSF p-tau/Aβ42 and One-card learning performance as measured 
by arcsine-corrected accuracy. 95% confidence interval for the regression line is displayed. 
R2=.139.
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Table 1
Participant characteristics
Sample characteristic Total Sample
(N=469
Cognitively Impaired
(n=70)
Cognitively Normal
(n=393)
p-value*
Age at CogState (years) 64.81 (6.6) 66.26 (6.1) 63.39 (6.6) .001
Sex (% female) 67.0% 57.1% 68.4% .064
APOE4+ 39.0% 37.1% 38.7% .808
Family History of AD 74.4% 67.1% 75.6% .137
Education (years) 16.50 (2.6) 16.40 (2.9) 16.53 (2.6) .703
WRAT reading standard score** 106.35 (9.2) 105.17 (11.2) 106.57 (8.8) .242
WRAT reading raw score** 51.17 (4.4) 50.41 (5.4) 51.31 (4.2) .189
Depression (CES-D) 6.21 (6.6) 6.30 (5.8) 5.93 (6.1) .634
Computer familiarity*** 4.74 (0.7) 4.56 (1.0) 4.77 (0.7) .097
Values are Mean (SD) unless otherwise indicated.
*
P-value is for chi square or t-test comparing Cognitively Impaired and Cognitively Normal groups.
**
WRAT reading standard scores in addition to raw scores are reported for easier interpretation, but raw scores were used in all statistical models 
to main consistency with other variables which were not standardized for age and sex. Computer familiarity was measured on a 1–5 scale where 
“1” corresponds to using a personal computer “once a year or less” and “5” corresponds to using a personal computer “every day or about every 
day.” APOE4=apolipoprotein E4 allele. WRAT=Wide Range Achievement Test. CES-D=Center for Epidemiological Studies Depression Scale.
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Table 6
Biomarker correlations with CogState and traditional neuropsychological tests
Cognitive Test
Biomarker
PiB burden PiB burden(outlier removed)
CSF
p-tau/Aβ42
CSF NFL
CPAL errors −.002 −.023 .203 .305
GMCT moves/sec −.083 −.089 −.102 −.296
GML errors .030 .006 .118 .219
GMR errors .057 .035 .165 .217
OCL accuracy −.141 −.115 −.347 −.204
ONB accuracy .072 .111 −.018 −.148
TWOB accuracy −.120 −.121 −.007 −.069
RAVLT delayed .120 .105 −.235 −.378
Logical Memory delayed −.053 −.026 −.199 −.300
BVMT-R delayed −.121 −.100 −.192 −.257
Spearman correlation coefficients are reported. Significant (p<.05) results are bolded. Trends (p<.1) are italicized. Accuracy was transformed using 
the arcsine proportion to correct for normality.
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